Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on September 14, 2004. The filing addresses a corporate governance update regarding the company's Bylaws.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report does not contain financial statements or performance metrics.
Material Changes
The Board of Directors amended Section 24(a) of the company's Bylaws. The amendment restricts the delegation of final action on specific transactions to the Executive Committee:
- Previous Limit: The Board could not delegate final action on acquisitions or dispositions exceeding $25 million.
- New Limit: The Board may not delegate final action on acquisitions, divestitures, and equity investment transactions exceeding $25 million in upfront payments or $100 million in upfront and conditional milestone payments.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notice of the Bylaw amendment.
Key Facts for Investor Verification
- Effective date of the Bylaw amendment: September 14, 2004.
- The threshold for Executive Committee delegation on acquisitions/divestitures remains at $25 million for upfront payments.
- A new threshold of $100 million applies to the total of upfront and conditional milestone payments for acquisitions, divestitures, and equity investments.
- The amendment was signed by Sandra Leung, Secretary, on September 17, 2004.